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Melanoma is a devastating disease, and while a number of targeted therapies are used 
to treat patients with malignant melanoma, tumors become resistant. Understanding tumor 
response to targeted therapies and how therapeutic strategies fail is a critical challenge in 
modern oncology. To investigate tumor behavior and response to a selective small molecule 
inhibitor of MEK1/2 (Trametinib) in vivo, we developed an intravital imaging approach to directly 
visualize drug response in a BRAFV600E/PTEN-null mouse model of melanoma by genetically 
incorporating a tdTomato fluorescent reporter allele (tdTomatoLSL). Through highly localized 
application of tamoxifen (4-HT) and noninvasive, serial intravital microscopy, I was able to 
directly visualize formation and progression of tumors at the single cell level in situ longitudinally 
over time. I directly imaged primary tumors in mice throughout treatment with MEKi and 
observed changes in tumor cell behavior during drug response for twelve weeks. I identified a 
clear relationship between bundled collagen and tumor cell survival in response to MEKi and 
collaborated with the Johnson lab to couple this model with transcriptome and kinome 
reprogramming analysis. Molecular analysis of tumors at early and late stages on MEKi 
identified a phenotypic shift toward an epithelial phenotype, characterized by c-Kit activity and 
the induction of a EMT_down and PI3K/AKT survival pathway signatures for melanoma 
persistence in vivo. Together, these approaches give a holistic view of the complex changes of 
tumor cells and stromal tissue in response to targeted therapy and provide insight for future 
treatment strategies.  
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CHAPTER 1: INTRODUCTION 
 
 1.1 Introduction and a brief description of melanoma 
Melanoma is the most dangerous form of skin cancer, which arises when a melanocyte 
within the dermis aberrantly proliferates, generating a tumor cell mass. Melanocytes are 
dendritic cells within the dermis and epidermis that secrete melanin-containing melanosomes to 
keratinocytes in the epidermis to protect them from UV-mediated DNA damage. UV irradiation is 
the main carcinogen associated with melanoma development, as it causes T-T dimers within 
DNA, which can induce genetic mutations that lead to aberrant cell survival and growth 1. 
Melanocytes can protect the skin from UV damage through melanosome secretion. However, a 
balance must exist between melanin production and sunlight exposure, as ultraviolet B is 
required for vitamin D synthesis, which is necessary for proper bone development 2.  
Similar to other types of cancers, melanoma is typically a disease of the elderly. 
However, the incidence of melanoma is steadily rising due to both an increase in detection 
methods and changes in behavioral trends, such as “tanning”, which has become culturally 
popularized over the past several decades. To drive aberrant growth within a single melanocyte, 
genetic mutations within both an oncogene and a tumor suppressor gene must occur to 
deregulate cellular signaling and cause a melanocyte to divide unchecked. Fortunately, in most 
cases, constitutive activation of pro-proliferative oncogenes (e.g. BRAF, NRAS, KIT, PI3K) will 
initiate oncogene induced senescence (OIS), which is a protective mechanism to inhibit tumor 
formation. In the case of most nevi formation, activation of this pathway will result in a round 
mole or an age spot 3. Additionally, while UV irradiation is the largest risk factor in developing 
melanoma, hereditary genetic variance can also predispose and increase one’s risk of 
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developing this disease, similar to other cancers. Common pathways associated with increased 
risk that can drive malignant progression are described below and are depicted in Figure 1.1.  
While melanoma only accounts for approximately 2% of all skin cancers, it is by far the 
most aggressive 4. Melanoma cells are particularly perilous in clinical settings because they are 
highly migratory, invasive, and they can metastasize very quickly to distant target organs 
including lymph nodes, lung, liver, and brain (Fig. 1.2). Once this cancer has metastasized, a 
patient has only approximately a 15% chance of surviving within the next 5 years. While new 
treatment strategies for malignant melanoma have been on the rise and may increase a 
patient’s life expectancy, tumors almost always regrow and become resistant to the therapy, 
which inevitably fails.  
1.2 Commonly deregulated pathways that promote melanoma growth 
 The most commonly mutated oncogene in malignant melanoma is BRAF, a key player in 
the MAPK signaling pathway, promoting cell growth and division when activated (Fig. 1.1). 
Mutations in this gene are detected in greater than 50% of human melanomas, with 
BRAFV600E being the most commonly identified mutation in the clinic 5. When this mutation 
(BRAFV600E) occurs, the kinase’s activation loop (residues 596-600) does not bind to inhibit 
the P-loop (residues 464-471), which associates with the phosphate group in ATP for BRAF 
kinase activity 6. Therefore, this mutation enables constitutive activity of BRAF and promotes 
activation of MEK, which is directly downstream in the MAPK pathway. 
In addition to gain of function in the BRAF oncogene, a loss of function mutation in a 
tumor suppressor gene, which can signal the cell to stop dividing, must also occur to form a 
tumor. The phosphatase PTEN is the second most commonly mutated tumor suppressor in 
cancers, second only to p53, and PTEN loss has been shown to cooperate with BRAFV600E to 
form melanoma 7,8. Loss of PTEN causes deregulation of the PI3-Kinase and AKT signaling 
pathways, which will deregulate cell checkpoint mechanisms, promoting cell growth and 
avoiding apoptosis.  Mapping the signaling pathways that promote survival has defined specific 
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kinases for therapeutic targeting. However, understanding the functional biology of melanoma 
development at the cell level is also important for identifying tumor behaviors that can be 
targeted with new therapies. 
1.3 Mechanisms of invasion & metastasis 
Melanoma is the most dangerous form of skin cancer because it quickly metastasizes 
(Figure 1.2). Traditionally, metastasis is known to occur through both lymphatic and 
hematogenous spread. Melanoma cell dissemination via the lymphatics is the most common, 
can occur at very early stages (between stage I and II), and results in tumor cell seeding within 
regional lymph nodes. Hematogenous metastasis occurs when tumor cells invade into and 
migrate through the vasculature to later form colonies in target organs, such as the liver, lungs, 
bone, and brain 9. This typically occurs in tumors at later stages (stage III or IV), and is a strong 
indicator of poor prognosis. Interestingly, it is now believed that melanoma cells may also 
migrate through a variety of other mechanisms to achieve metastasis. For instance, tumor cells 
may migrate along nerve fiber tracks, use vascular mimicry to invade and migrate along 
endothelial cells, degrade or reorganize extracellular matrix to promote migration and invasion 
away from the original tumor mass, or recruit a variety of stromal cells and factors to enhance 
their metastatic capacity 10,11.  
Previously, it was widely held that the process of invasion and metastasis occurred via 
migration of single cells. However, now many studies are now revealing that metastasis may 
involve, or in fact require, collective migration of multiple cancer cells from the primary tumor 
12,13. Work in the cancer stem cell field has shown that cancer stem cells can attach themselves 
to more pro-migratory tumor cells, which do most of the heavy lifting in the metastatic cascade. 
In this model, migratory tumor cells invade through the endothelial barrier to transport both itself 
and the attached cancer stem cell through the blood stream and extravasate into distant tissue. 
It is thought that here, the tumor stem cells, which are pro-proliferative, are then responsible for 
the development of micrometastases and colonization of target organs to form secondary and 
 4 
tertiary tumors. As outlined in Table 1.2 and discussed below in further detail, there are limited 
mouse models of melanoma that can properly recapitulate the individual stages of tumor 
development that lead to the metastatic cascade in vivo. For this reason, among several others, 
it remains unknown whether existing therapeutics promote, inhibit, or have no effect on tumor 
cell invasion and dissemination. We hope to use the melanoma model system that I have 
developed in my graduate career to mimic and interrogate metastasis as it occurs in clinical 
settings, which will be discussed in further detail in Chapter 3.  
1.4 Treatment strategies and issues 
Since cancer is such a dynamic and heterogeneous living tissue, there are a great 
number of challenges in successfully treating this disease. While a melanoma is primarily 
composed of quickly proliferating melanoma cells, the tumor stroma can also promote 
malignancy and resistance to therapeutics. A variety of cell types and factors influence the 
tumor microenvironment 14. Infiltrating immune cells such as tumor associated macrophages 
(TAMs); cancer associated fibroblasts (CAFs), which can remodel the ECM; endothelial cells 
that make up the leaky tumor vasculature; hair follicles that provide a stem cell niche; nerve 
fibers; lymphatic vessels that can promote tumor cell dissemination; and soluble factors can all 
promote tumor cell persistence and growth.   
A number of therapeutic strategies exist to treat patients with melanoma, and specific 
options are suggested depending on disease state (Table 1.1). If found early, surgical removal 
of a melanoma can inhibit tumor spread, providing the only “cure”. Beyond surgery, radiation is 
a common strategy to suppress disease progression. While radiation decreases tumor size, it 
causes many undesirable side effects in patients and does not necessarily prolong life 
expectancy 15. Immunotherapy is a newer strategy that is growing in popularity, with more drugs 
becoming available in clinical trials. While studies are ongoing, melanomas have been shown to 
shrink, and a small population of patients have experienced remission; however most tumors 
eventually become resistant to immunotherapeutics, as occurs with targeted therapy 16–18. 
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Targeted therapy is standard of care, as selective small molecule inhibitors against BRAF and 
MEK, which are key players in the MAPK pathway, have prolonged patient lives in late stages. 
However, tumors can ultimately become resistant to these inhibitors through a variety of 
mechanisms, which are still under investigation.  
For patients with late stage melanoma, chemotherapy remains one option for prolonged 
survival. Chemotherapy is not the most desirable treatment for patients, since it is extremely 
taxing, causes a number of horrible side effects, and resistance is still common in late stages 15. 
While some labs are already using intravital imaging to interrogate the effects of chemotherapy 
in vivo, it remains unclear how tumors develop resistance to drug over a long period of time 19. 
Therefore, it is critical to identify mechanisms that cause resistance to all types of therapeutics 
so that we can develop new treatment strategies for patients with metastatic melanoma, 
especially in later stages. To do this, we must develop animal models of melanoma that are able 
to fully reproduce the stages of tumor progression and resistance to therapy. 
1.5 Modeling melanoma in mice 
 The characteristics of melanoma development and resistance to therapeutics remain 
difficult to study, as there currently exist few models of melanoma that properly mimic this 
process in vivo as it occurs in patients. Current commonly used models of melanoma growth, 
metastasis, and drug response only touch on some of the true aspects of melanoma 
progression (Table 1.2). For example, tail vein injection models are still the gold standard in 
assessing a tumor cell line’s metastatic potential. However, this model assesses up to one 
million tumor cells’ ability to colonize in the lungs within a short period of time, and does not 
properly recapitulate the intricate stages that a single tenacious melanoma cell must accomplish 
to reach and colonize tissue in a secondary location. 
A variety of mouse strains are used in murine tumor models. For most transplant 
models, where melanoma cells are injected into the animals, immune-compromised mice must 
be implemented to ensure that the implanted cells are not cleared by the immune system, which 
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would defeat the purpose of the study. There are four classes of immunodeficient mice that can 
be used in these studies 20. “Nude” mice are homozygous for the Foxn1nu mutation, which is 
required for both hair follicle and thymic development. Loss of this gene results in mice that lack 
T-cells, which are critical players in adaptive immunity. Though not always the most reliable in 
tumor take rate, nude mice are arguably the most popular of the four classes, as they have an 
intact innate immune system and are the least expensive. “Scid” mice, homozygous for the 
Prkdcscid mutation, which inhibits rearrangement of T-cell receptor (TCR) and immunoglobulin 
(Ig) genes, lack both T and B-cells. “Rag-deficient” mice are very similar to Scid mice, as they 
also lack both T and B-cells, however this phenotype is achieved through expression loss of 
both Rag1 and Rag2. Finally, “higher order, multigenic” mice are generated using the Scid or 
Rag-deficient background, but have additional alleles to inhibit both acquired and innate 
immune function. These mice lack T and B-cells due to their background, but because of 
additional mutations, they also lack natural killer (NK) cells and loss of macrophage and 
dendritic cell function. The more immunocompromised the mouse, generally, the higher 
likelihood that the tumor implantation will successfully grow in the model, which is especially 
critical in drug studies trying to assess the likelihood of a patient tumor to respond to a specific 
therapeutic. However, use of these mice for in vivo tumor studies is problematic, as the complex 
tumor microenvironment plays a significant role in the overall function and survival of patient 
tumors. There remains a substantial need for mouse models that properly mimic endogenous 
tumor formation and drug response in an immune-competent setting to classify and inform 
therapeutic efficacy.  
While there already exist a significant number of mouse models that can recapitulate 
certain aspects of tumor biology and behavior in vivo, there’s a significant need to improve 
these models to more precisely mimic clinical settings (Table 1.2). To achieve this, mouse 
models should provide precise spatiotemporal control of tumor initiation and growth in an 
endogenous and immune-competent setting, they need to enable long-term longitudinal studies 
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of drug response, through to the point of tumor resistance and regrowth on drug, and they 
should be readily coupled with molecular profiling techniques to asses and identify important 
players in resistance mechanisms for future targeting. Additionally, the ideal model should 
enable direct visualization of tumor behavior at the single cell level, which will pave the way to 
identify key patterns of tumor cell behavior over time throughout development and, ultimately, 
drug response. Given our expertise in and appreciation for imaging, we thought this could be 
accomplished via coupling an inducible endogenous mouse model of melanoma to intravital 
imaging. Spoiler alert: we were right.  
1.6 Using intravital imaging to study cancer 
Quantitative light microscopy has been one of the fastest growing areas of scientific 
research over the past two decades. With the identification and genetic use of fluorescent 
reporters and quickly developing technologies in analytical software and imaging modalities, 
microscopy has arguably become the most illuminating tool in biological investigations 21–23. The 
use and visualization of cell culture systems and model organisms have significantly enhanced 
our understanding of basic biological functions. While cell culture systems provide direct insight 
into specific roles for a lab’s favorite protein (e.g. actin), these studies are performed outside of 
the cell’s natural endogenous environment. As the field grows, it is becoming increasingly 
imperative to perform imaging experiments in relevant environments, as the micro- and macro- 
environment outside of the cell plays a significant role in cellular behavior and can influence 
scientific findings 24.  
 With this in mind, neurobiology, immunology and cancer biology fields are swiftly moving 
toward incorporating intravital imaging platforms and techniques 25. “Intravital microscopy” is the 
use of microscopy in living organisms, specifically in live mammalian models (e.g. mice, rats). 
This is particularly important for studies in tumor biology. Although a tumor mass is primarily 
composed of the cancer cells themselves, there is an extensive and complex stromal 
microenvironment that plays a critical role in tumor development, persistence, dormancy and 
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metastasis. Therefore, while significant information can be gleaned from tumor cell studies in 
vitro, it is also critical to investigate tumor behavior within the endogenous microenvironment.  
 Multiple microscopy systems can be used for intravital imaging approaches 26. First, 
widefield microscopy, though it is relatively inexpensive and enables quick acquisition, is not 
ideal because it achieves extremely limited depth in a tissue and readily induces photo-
bleaching due to off-focus emissions. Secondly, both confocal and spinning disk systems may 
be implemented, which provide improvements compared to widefield systems as they have 
increased spatial resolution and reduced photo-bleaching 27. These systems are commonly 
used to image cellular behaviors in subdermal organs through surgically implanted glass 
windows 28. Thirdly, multiphoton microscopy, though the most expensive option, provides the 
best imaging modality for thick tissues as it enables resolution of deeper structures compared to 
confocal, and provides limited off-target photon emissions and limited photo-bleaching 29. 
When imaging in vivo, multiple challenges arise. Through solid tissue, photons from both 
the excitation beam (laser) and the emitted photons from the sample or region of interest are 
scattered, and the deeper the targeted tissue is, the more challenging it is to excite and detect 
emitted photons. If the cells, tissue, or structure of interest is more than 50-100µm below the 
surface, resolution will be lost unless studies are performed via multiphoton imaging, which 
enables emission and detection of photons with further penetration depth (up to 500µm). Two-
photon microscopy, which is what I used for my studies, relies on two photons with wavelengths 
in the near infrared or infrared (IR) spectrum, which still may have a variable penetration depth 
depending on the tissue type. Overall, the more heterogeneous a tissue is, the more readily 
photons will scatter as different tissue components may have different refractive indexes 30. If 
imaging is being performed ex vivo, some of this scattering effect can be alleviated through 
tissue “clearing” mechanisms and protocols 31.  
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Led by Keefe Chan, a previous postdoctoral fellow in the Bear lab, we established a two-
photon imaging system in mice ears 32. Using our intravital platform, we can stabilize mice 
underneath the objective on a heating pad for imaging studies lasting less than three hours at a 
time, using 1-2% isoflurane (reference Figure 2.2). I have incorporated this system in other 
collaborative studies, two of which were published in 2015 by the DeSimone lab, and two others 
now in review 33,34. 
 An additional benefit to two-photon microscopy is that this modality also enables the 
second harmonic generation 35. This allows direct visualization of bundled collagens, myosins, 
myelin, and lipids with no energy absorption. For my studies, tuning the laser to 1050nm 
enabled simultaneous detection of bundled collagen through the second harmonic along with 
the fluorescent reporter tdTomato, which marked the endogenous melanoma cells within the ear 
dermis. Throughout my dissertation, I will address how I used this two-photon intravital imaging 
system to investigate the roles and interactions between endogenous melanoma cells and 
bundled collagen within the dermis of the mouse ear throughout tumor development and 

















Figure 1.1 Commonly deregulated pathways in melanoma. Activation of receptor tyrosine 
kinases (RTK’s) elicits downstream signaling pathways outlined in this diagram, which play 
critical roles in cell survival or death. Deregulation of these pathways in melanocytes can induce 
melanoma development. Items underlined in green suggest proteins or processes that promote 
melanoma cell growth and survival, while red underlines mark tumor suppressive functions. 
Underlined items are factors that are highly relevant to my thesis works and are referenced 









Figure 1.2 Stages of melanoma progression. Graphical representation of melanoma growth 
within the dermis from a single melanocyte, through to the point of invasion through 
subcutaneous tissue and the cartilage boundary to undergo hematogenous spread. The 
different clinical stages of melanoma are represented above each section, “0” representing 
melanoma in situ, “IV” representing late stage malignancy. The associated steps within the 





























Table 1.2 Existing mouse models for melanoma research. List of different types of mouse 
models that are commonly used to study cancer. Each has deficits in mimicking human disease; 















CHAPTER 2:  BRINGING INTRAVITAL IMAGING TO A GEM MODEL OF MELANOMA 
ENABLED DIRECT VISUALIZATION OF TUMOR DEVELOPMENT AND IDENTIFICATION 
OF FACTORS IN EARLY RESISTANCE TO THERAPY 
 
This work is being submitted to the journal Cancer Research. Hailey Brighton designed 
experiments and performed the intravital imaging, histology preparation and imaging, data 
analysis, and prepared the manuscript. Steve Angus designed and performed the MIB/MS and 
mRNA-seq experiments, molecular data analysis, western blotting, and helped prepare the 
manuscript. Kubra Karagoz, Noah Sciaky and Michael L. Gatza performed molecular analysis of 
mRNAseq data. James Bear guided overall experimental design, data interpretation and helped 
prepare the manuscript. Tao Bo and Alicia Tagliatela helped with animal experiments. Jose 
Roques and David Darr helped with animal development and provided Trametinib for our 
experiments. Norman Sharpless and Gary Johnson were involved in the study design and 
interpretation of results. James Bear guided experimental design, data interpretation, helped 
prepare the manuscript, and funded this work.  
2.1 Overview 
While existing targeted therapies (Trametinib, Dabrafenib, and Vemerafenib) against 
malignant melanoma have extended patient lifespan overall, melanoma inevitably becomes 
resistant to drug and disease progresses. This process of drug resistance remains a huge black 
box in cancer research. For my primary thesis work, I focused on interrogating the effects of 
Trametinib, a selective small molecule inhibitor of MEK1/2, on endogenous tumor behavior in 
vivo. To directly visualize melanoma development and drug response at the cell level in situ, we 
genetically incorporated a tdTomato fluorescent reporter allele into an existing inducible GEM 
model of BRAFV600E / PTEN-null melanoma. I developed a precise application method of 4-
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HT, which enabled spatial and temporal control of melanoma growth in a reproducible fashion, 
and I performed longitudinal imaging studies of tumors via two-photon intravital microscopy. By 
treating mice with MEKi over the course of three months, I was able to identify adaptive 
changes within the spatial relationship between tumor cells and bundled collagen for persistent 
survival on drug. Furthermore, molecular analysis of tumors at early and late stages on MEKi 
via mRNA-sequencing and MIB/MS enabled us to identify plastic changes in kinome activity and 
protein expression during melanoma response to MEKi.  
2.2 Introduction 
Activating mutations in the MAPK pathway drive malignant transformation in melanoma, 
with BRAF(V600E) being the most common driver in patient settings 36–38. Clinical use of 
selective MEK and BRAF inhibitors have extended life expectancy in patients with malignant 
BRAF-mutant melanoma and are now the standard of care (Flaherty. et al., 2012; Long et al., 
2014; Wellbrock and Arozarena, 2016). However, long-term success of targeted therapy is 
limited, as tumors ultimately become resistant and disease progresses, even in patients given 
BRAFi/MEKi combination therapies (Karimkhani, Gonzalez and Dellavalle, 2014; Larkin. et al., 
2014; Long et al., 2015). Melanoma can become refractory to therapy via a variety of acquired 
mechanisms. For one, PI3-K and AKT pathways can increase activity, bypassing the need for 
MAPK to inform the cell to proliferate 44. Additionally, enhanced expression of receptor tyrosine 
kinases, such as c-KIT, FGFR and EGFR may occur, and BRAF variants such as CRAF and 
ARAF may compensate for loss of BRAF activity 45,46. However, there still exists a substantial 
need for relevant preclinical models to analyze therapeutic response in vivo in order to make 
better prognostic predictions and to inform treatment strategies 47.  
A complex variety of genomic, epigenetic and extracellular factors all affect how 
melanoma responds to and resists therapeutic intervention. Evidence of “phenotype switching” 
at the molecular level has also been identified as a relevant mechanism for how tumors become 
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resistant to targeted therapy 48–50. Via this mechanism, tumor cells may adapt a stem-like 
phenotype, and a “switch” from epithelial to mesenchymal phenotype has been documented in a 
variety of tumors in response to drug, which is thought to promote malignancy and therapy 
resistance (Roesch, 2016).  
Melanoma cell heterogeneity, which is driven by both switches in molecular expression 
and changes in the extracellular microenvironment, also influences therapeutic resistance 
(Straussman et al., 2012; Smith et al., 2014; Roesch, 2015). Exactly how the extracellular matrix 
(ECM) affects tumor response to drug remains unclear. It is known that collagen in tumors is 
commonly cross-linked in linear bundles, which can stiffen the microenvironment and elicit 
downstream signaling events that promote tumorigenesis 54,55. Improving our understanding of 
how therapeutics influence the ECM within the tumor microenvironment is critical, as collagen 
deposition and reorganization may promote melanoma cell invasion, malignancy and resistance 
through multiple mechanisms 56,57. Furthermore, intratumoral regions with high stromal cell 
concentrations have been shown to promote tumor cell persistence against BRAF inhibitor 
(Hirata et al., 2015). Modeling ECM behavior in tumor development and drug response through 
proper in vivo strategies can help uncover new therapeutic approaches and targets 59.  
To address the challenges of modeling response and resistance to targeted therapies, 
we have extended an existing Tyr::CreER; BRAFCA;PTENlox/lox (PBT) GEM model of melanoma 
by crossing in a lox-stop-lox tdTomato fluorescent reporter allele (tdTomatoLSL) 7,60. The 
incorporation of this allele enables direct tracking of endogenous melanoma development over 
time through noninvasive intravital imaging, as well as imaging therapeutic response. With a 
highly-localized application method of 4-Hydroxy-tamoxifen (4-HT) on the mouse ear, we have 
achieved precise spatiotemporal control of melanoma initiation. Using this approach, we directly 
visualized tumor and collagen reorganization throughout development and response to 
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Trametinib (MEKi), and identified changes in molecular behavior through transcriptome and 
kinome reprogramming analysis at early and late stages on MEKi.   
2.3 Results 
A Specific 4-HT-application method enables spatiotemporal control of tumor growth  
While inducible Genetically Engineered Murine (GEM) models of cancer have enhanced 
our understanding of tumor biology and therapeutic response, there exists a significant need to 
improve these models for translational research 61. The ability to control endogenous tumor 
initiation in time and space is a critical experimental variable that needs to be improved to better 
model melanoma as it occurs in patients. We developed a precise induction method, where 1μL 
of 20mM 4-Hydroxytamoxifen (4-HT) was applied to the middle of the mouse ear for 8-10 
minutes and carefully removed and washed. We chose to induce melanoma on the ear because 
the skin of the mouse ear contains a population of intrafollicular melanocytes that more closely 
mirrors human skin, and the ear provides a flat surface for stable intravital imaging. Our imaging 
strategy incorporated a tdTomato fluorescent reporter allele (tdTomatoLSL) in the existing 
tamoxifen-inducible PTEN-null / BRAFV600E (PBT) melanoma GEM model (Fig. 2.1A). This 
method of 4-HT application yielded reliable local tumor formation on mouse ears in a 
reproducible fashion, with tumors forming at 100% success rate (Fig. 2.1B, Fig. 2.2F). 
Additionally, precise spatiotemporal control of melanoma induction in this GEM model extended 
animal lifespan (normally limited by multiple primary tumors), which enabled long-term 
longitudinal in vivo studies of melanoma development and, later, drug response. 
Visualizing the process of endogenous tumor progression from early stages has been a 
relative ‘black box’ in the field, as most existing models cannot be used to track tumor cell 
behavior over time in situ. We used two previously described intravital imaging methods to 
interrogate tdTomato+ PBT melanoma behavior both at the macroscopic (mm) and microscopic 
(um) scale using a stereomicroscope and a multiphoton microscope, respectively (Fig. 2.2A, B) 
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32. Using anesthetized animals, we positioned them on a heating pad and stabilized the ear with 
a custom designed ear clamp during imaging. With multiphoton imaging, we were able to 
quantify the original number of recombined melanocytes post-induction. Less than 2 days after 
4-HT treatment, we identified individual recombined endogenous melanocytes within the dermis 
(Fig. 2.2). At this stage, we counted the tdTomato+ melanoma cells in a 1.2mm2 region 
(140cells/mm2) and approximated the total number of recombined cells that are initially induced 
by measuring the average area of the 4-HT droplet (2.77mm2, n = 20) (Fig. 2.2C, D). We 
determined that less than 400 melanocytes were recombined in this system using an initial 
20mM concentration of 4-HT. Additionally, we identified different populations of recombined 
tdTomato+ cells, including both intra- and inter-follicular melanocytes within the dermis (Fig. 
2.2E arrows).  Furthermore, breeding out the Ptenlox/lox and BRAFCA alleles yielded a control 
Tyr::CreER; tdTomatoLSL mouse line for comparison with nontumorigenic fluorescent 
melanocytes, which were dendritic and did not proliferate to form melanoma (Fig. 2.4A).  
Next, we imaged PBT melanoma progression from early stages serially over time to 
characterize melanoma development in this model. Tracking tumors each week post-4-HT- 
application via transmitted light and fluorescence imaging revealed stages of tumor growth that 
were reproducible from tumor to tumor at different time points (Fig. 1C). At the macroscopic 
level, melanoma initially spread radially, forming a palpable tumor mass within 6-8 weeks post-
application of 4-HT, and we observed relatively homogeneous tdTomato distribution throughout 
tumor growth (Fig. 1D). Melanoma growth, measured by tumor depth, was exponential, and 
there was no evidence of tumor development in other regions on the animal, mimicking human 
disease (Fig. 2.1E, Fig. 2.2G).   
Longitudinal intravital imaging reveals distinct phases of melanoma development 
Multiphoton imaging provided a platform to simultaneously visualize tdTomato+ 
melanoma cells and second harmonic generation (SHG), which enabled detection of the 
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bundled collagen fiber network in the tumor microenvironment (Fig. 2.2E) 62. Using the SHG as 
a guide, we visualized the tumor cells throughout the dermis (depth range of 30 µm to ~200 
µm), between the epidermis and the cartilage layer in the middle of the mouse ear. In addition, 
we identified known structures such as hair follicles, which are evident by their circular structure 
and a center devoid of fluorescence.  
By tracking the tdTomato+ melanoma cells in concert with the SHG, we followed 
melanoma development from early stages with cellular resolution, and we identified distinct 
phases of growth (Fig. 2.3A, Fig. 2.3B). During the “proliferation phase”, the first few weeks 
post-4-HT application, we identified clonal populations of melanoma cells arising directly in the 
dermis. These regions of concentrated tdTomato+ cells expanded over time to become densely 
packed pre-tumorous lesions. From there, endogenous melanoma spread radially throughout 
the dermis, during the “pre“ and “early tumor” phases, where the dermis became dense with 
tdTomato+ melanoma cells. During this phase, SHG signal was significantly reduced, 
suggesting degradation of bundled collagen and the extracellular matrix. Here, we also clearly 
identified the tumor boundary in the ear at the cell level (Fig. 2.4C white line). Finally, the “late 
tumor phase”, 7+ weeks post-4-HT application, corresponded with the vertical growth phase in 
patient settings, as melanomas rose above the original flat surface of the ear (Fig. 2.1D, Fig. 
2.3A). Fluorescence intensity analysis at these different stages of tumor development further 
recapitulated our ability to model clinical tumor growth, as tdTomato signal increased and the 
second harmonic signal decreased over time (Fig. 2.3B, C).  
 To compare our ad-hoc intravital staging series to more traditional approaches, we used 
classic histology techniques to characterize tumor progression in this model via H&E staining. 
Consistent with our intravital imaging, tissue thickness increased over time, and infiltration of 
stromal cell populations and increased tumor cell concentrations were evident (Fig. 2.3D). 
Masson’s Trichrome (MT) staining further demonstrated the degradation of bundled collagen 
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post-4-HT application, as collagen staining abrogated over time (Fig. 2.3E). Since the tdTomato 
signal was conserved after tissue processing for histology, we also performed fluorescence 
microscopy of histological sections to visualize tumor development at different phases (Fig. 
2.3F, 2.4D). With this technique, in the “proliferation phase” two-weeks post-4-HT application, 
we saw a small population of tdTomato+ cells on the dorsal part of the mouse ear where 4-HT 
was applied. In the early and late tumor phases, however, we identified vertical growth in both 
ventral and dorsal regions of the ear, and at 8 weeks post-4-HT application, we identified 
melanoma cell invasion beyond the cartilage layer in the middle of the ear (Fig. 2.4D).  
 Through defining distinct phases of melanoma development in situ from the initial time 
point, our system provides a mechanism to visualize tumor cell behavior in a variety of different 
investigative platforms. We envision that this system can be used to interrogate distinct and 
relevant hallmarks of early tumor behavior in vivo, such as tumor angiogenesis, tumor-stroma 
interactions, and invasion prior to vertical growth 63. However, since our main objective was to 
create a model of long-term patient response to therapy, we used this system to probe the 
longitudinal effects of the selective MEK1/2 inhibitor, Trametinib, on melanoma behavior at the 
cellular and molecular levels.  
Melanoma response to MEKi over time is heterogeneous 
Since the mechanisms of resistance to BRAF inhibitors in BRAF-mutant melanoma have 
been thoroughly investigated in other models, we focused on examining endogenous melanoma 
response to the selective allosteric MEK1/2 inhibitor, Trametinib. To investigate how targeted 
therapy affects tumor behavior at the macroscopic and cellular levels in this model, we fed MEKi 
to mice 8-9 weeks post-4-HT application, beginning at the late tumor phase, and serially imaged 
melanoma response to drug using intravital imaging. MEKi was incorporated into the food 
(Research Diets) with a daily dose of 0.3 mpk, and food intake was calculated using the 
Jackson Laboratory’s Phenome Database, as in previous studies 64. Since tumor development 
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is spatiotemporally controlled in our model, we were able to extend drug treatment and visualize 
both PBT melanoma response to MEKi and tumor regrowth (after 12 weeks on MEKi), 
mimicking tumor response to targeted therapy in patient settings.  
Without drug treatment, tumors grew exponentially in a spatially defined region with 
relatively homogenous tdTomato expression throughout continued growth (Fig. 2.5A, C). 
Tumors responded quickly to MEKi treatment, however, with approximately 30% reduction in 
tumor size within the first week (Fig. 2.5B, D). Given enough time on therapy, disease 
progressed and tumors regrew, returning to their original size within 12 weeks. Interestingly, 
tumor response was heterogeneous even at the macroscopic level, with some regions of 
persistent tdTomato signal and other regions devoid of fluorescence, some of which were re-
populated with tdTomato+ cells at late stages on MEKi (Fig. 2.5B arrows). These results 
suggest evidence for both intrinsic and acquired functional resistance to MEKi in this model and 
demonstrate that drug response is heterogeneous. 
MEKi induces intratumoral reorganization  
We sectioned tumors at early and late stages on MEKi for histology and found changes 
in tumor cell organization and melanin expression over time, through brightfield and 
fluorescence imaging (Fig. 2.5E). Before drug treatment, tumor cells aggregated within the 
dermis but aligned with elongated and spindle-like morphologies closer to the cartilage 
boundary (Fig. 2.6A, B top panel). Early on MEKi, we identified intratumoral nests within the 
dermis, where tumor cells organized in a dense circular fashion (Fig. 2.6B middle panel, C). 
Tumor nests have been described as regions of promoted growth in melanoma, and at this 
stage on MEKi, they may indicate structures that promote therapeutic resistance 65. There was 
also a reduction in tdTomato+ cells near the cartilage layer, and tumor cells distal from the bulk 
of the tumor mass were more dendritic compared to pre-drug. At the late stage on MEKi during 
tumor regrowth, tumor nests were less obvious in the dermis, with elongated and aligned 
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melanoma cells again near the cartilage boundary (Fig. 2.6B third panel). Interestingly, tumor 
nests were identified in regions of tumor cell invasion through the cartilage boundary at the late 
stage on MEKi (Fig. 2.6D). Based on fluorescence imaging of histology sections, the density of 
tdTomato+ melanoma was enhanced in the late MEKi stage compared to pre-treatment, 
demonstrating that tumor regrowth was largely due to the tumor cells themselves (Fig. 2.5F, Fig. 
2.6B).  
Tumor cells co-localize with bundled collagen during initial survival on MEKi  
The extracellular matrix (ECM) in tumors is highly dynamic, and de-regulation of 
collagen crosslinking within the ECM has been shown to play a causative role in cancer 
pathogenesis 19,66. We used our multiphoton intravital microscopy system to identify critical 
changes and dependencies between tumor cells and bundled collagen between early and late 
stages on MEKi. Before therapy, the second harmonic generation signal (SHG) was low, 
demonstrating a loss or degradation of ECM in PBT tumors 9 weeks post-4-HT. However, MEKi 
treatment caused morphological changes and reorganization of tumor cells as early as 3 days 
on drug (Fig. 2.7A). Strikingly, tdTomato strongly co-localized with SHG during this phase, 
suggesting that the bundled collagen within the dermis of the ear played a role in tumor cell 
survival on MEKi (Fig. 2.7A, B). After several weeks of continuous treatment, this spatial 
correlation between tumor cells and bundled collagen structures remained strong (Fig. 2.7A, B). 
Furthermore, the tdTomato+ melanoma cell density increased over several weeks on MEKi, 
demonstrating microscopic tumor persistence prior to tumor regrowth. 
In the late stage (6-12 weeks on MEKi), (Fig. 2.5D), the correlation between tumor cells 
and bundled collagen structures diminished as the tumor regrew. At this stage, we observed a 
loss in spatial correlation and co-localization between tdTomato and SHG signals, and we 
identified regions of tumor cells independent of collagen and visa-versa (Fig. 2.7A white 
arrows). Through co-localization analysis between tdTomato and SHG signal, we were able to 
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measure this loss in tumor cell association with bundled collagen over time on MEKi (Fig. 2.7B). 
This suggests that over time, as MEKi loses efficacy and melanoma resists therapy, bundled 
collagen structures become less critical for tumor cell survival, which may be due to a significant 
change in tumor signaling or phenotype.  
Classical immunohistochemistry staining by H&E and Masson’s Trichrome (MT), 
revealed that extracellular matrix (ECM) deposition was greatly enhanced in the late stage 
compared to early on MEKi (Fig. 2.7C, 4D blue stain). Bundled collagen may play a significant 
role in tumor cell survival during the beginning of Trametinib therapy. While the ECM changed in 
character (deposition, location, concentration, distribution, organization), and bundled collagen 
increased during Trametinib treatment, the dependency on bundled collagen for tumor cell 
survival at the individual cell level diminished as treatment continued. 
Kinome profiling of the Trametinib response reveals potent MEK inhibition and adaptive 
kinome reprogramming  
Since we were able to visualize changes in drug response at the tumor cell level over 
time by intravital imaging, we sought to complement these insights by interrogating the 
molecular changes that occur at during Trametinib treatment. To identify reprogramming events 
in the kinome in parallel with our imaging studies, we harvested Trametinib-treated and control 
tumors and performed molecular analysis of tumor response (Fig. 2.8). We employed a 
chemical proteomics approach (multiplexed-inhibitor bead affinity chromatography coupled with 
mass spectrometry, MIB/MS) to assess the state of the kinome in our model. The adaptive 
response to targeted kinase inhibitors can lead to dramatic alterations in signaling and ultimately 
to drug resistance and tumor progression 67–69. We have previously used MIB/MS to 
characterize the adaptive response leading to therapeutic resistance to MEK inhibition in triple-
negative breast cancer and lapatinib in HER2+ breast cancer 70,71. The affinity purification 
involves a mixture of Type I kinase inhibitors to selectively enrich for kinases based on their 
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activation state, abundance, and affinity for the inhibitors. Untreated tumors and tumors from 
mice treated for 1 week (early) or 12 weeks (late) on Trametinib were harvested, snap-frozen, 
and processed for MIB/MS (Fig. 2.9A). As predicted, loss of MEK1/2 MIB binding (as 
determined by label-free quantification (LFQ) intensity) was dramatic compared to untreated 
control tumors and persisted throughout the duration of the experiment (Fig. 2.9B). The MIB 
binding of BRAF and ERK1/2 was also readily observed by LFQ intensity (2.10 4A-C). These 
observations confirmed that tumors from the Trametinib-treated mice displayed MEK inhibition 
coincident with the overall tumor depth decrease. 
To gain insight into the global kinome response in this model to MEK inhibition, the 
kinome data was processed with Perseus software and hierarchical clustering of the log2-
transformed LFQ intensities was performed (Fig. 2.9C). Notably, the majority of kinases 
exhibited a comparative loss of binding in response to Trametinib (Fig. 2.9C, inset). Despite the 
potent inhibition of MEK, a subset of kinases displayed a pattern of increased MIB binding over 
time (Fig. 2.9C, inset). These kinases included the RTKs c-KIT and Ephrin type-A receptor 1 
(EPHA1), the metabolic kinase FN3K, PTK6, the stress-associated kinase CDK5, and B 
lymphoid kinase (BLK). While a degree of tumor heterogeneity could be observed in the 
untreated and early time points, the late group appeared more similar in global kinome behavior. 
This observation was corroborated by principal component analysis of the kinome profile (Fig. 
2.10D). To visualize the magnitude and significance of the kinome changes, volcano plots were 
generated for the Early and Late Trametinib treated tumors relative to the untreated control 
group (Fig. 2.9D, E). As expected, MEK1 and MEK2 were strongly significant and MIB binding 
loss was large in magnitude. In contrast, kinases such as c-KIT, FGFR3, and BLK were most 
dramatically increased in response to Trametinib. These observations were confirmed via WB of 
tumor lysates (Fig. 2.9F), including loss of phospho-ERK1/2 and a decrease in total PDGFRβ. In 
addition, tdTomato levels were comparable across all of the tumors (Fig. 2.12E). This is in 
agreement with the in vivo tumor imaging showing the presence of tdTomato-positive cells at 
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this time point (Fig. 2.7). These experiments demonstrate the feasibility of chronological kinome 
evaluation in our melanoma model. Taken together, these data demonstrate the plasticity of the 
kinome from our melanoma model, even in response to a potent and selective inhibitor. The 
adaptive kinome response correlated with our intravital imaging observations and provided a 
deeper level of insight into endogenous melanoma persistence and functional resistance on 
MEKi.  
Transcriptome analysis reveals plasticity and phenotypic alterations in response to MEKi 
To assay changes in gene expression throughout MEKi treatment, we utilized sections 
of snap-frozen tumors harvested at early and late time points on drug for RNAseq analysis, and 
we compared expression changes with the adaptive kinome response observed by MIB/MS. As 
shown in Fig. 2.11A, hierarchical clustering of kinome gene expression in response to MEK 
inhibition revealed substantial and distinct changes at both early and late time points compared 
to untreated tumors. To identify differentially expressed kinases, we performed DESeq2 
comparing the early and late time points to control tumors and visualized the genes in volcano 
plots 72. After one week on Trametinib, the expression of numerous kinases was dramatically 
altered (Fig. 2.11B).  Amongst these changes, expression of Mek1/Map2k1 and Mek2/Map2k2 
was significantly decreased with Mek1 levels reduced more significantly and to a greater 
degree. Other kinases with diminished expression included the poorly characterized 
serine/threonine kinase Stk32a, Cdk18, Akt3, Epha3, and Alk. In contrast, the tumors harvested 
after one week of treatment displayed increased expression of the fibroblast growth factor 
receptors Fgfr2, Fgfr3, as well as Rps6ka1 (p90Rsk), and Ddr1, which we have observed in 
previous in vitro studies.  
At the late time point, Mek1/Map2k1 and Mek2/Map2k2 were not significantly altered 
(Fig. 2.11C). In contrast, the expression of kinases such as Cdk18, Alk, Akt3, and Stk32a was 
reduced more significantly and to a greater degree over the course of Trametinib treatment. 
Another kinase with increased gene expression at the late time point included Ntrk1, 
 26 
neurotrophic receptor tyrosine kinase, which is important for neuron development and survival 
and may play a similar role in melanoma. Additionally, expression of the non-receptor Src-
related tyrosine kinase Srms, thought to play a role in keratinocyte proliferation, was increased 
at the late time point (Fig. 2.11). Distinct from the early time point, the expression of lymphocyte 
kinases Itk and Zap70 was increased with MEK inhibition. Collectively, the kinome expression 
data suggested that chronic treatment with the MEK inhibitor, Trametinib, did not result in the 
sustained transcriptional depletion of Mek1 and Mek2. Instead, tumor persistence and regrowth 
was dependent on unique and diverse set of adaptive kinases in both the early and late time 
points.  
To directly compare the MIB/MS kinome profiles with RNAseq expression data, we 
plotted the fold-changes observed in kinome by each assay (Fig. 2.11D, E). At both the early 
and late time points, the inhibition of Mek1 and Mek2 was almost exclusively pharmacological, 
as determined by loss of MIB binding. However, the loss of Cdk18, Epha3, Epha7, and Stk32a 
was also observed at the transcript and signaling level. Additionally, the RTKs Met and Epha1 
were found to increase by both RNAseq and MIB binding (Fig. 2.11D, E), but expression of the 
RTK Kit was only significantly increased in the early stage, but displayed sustained MIB binding 
throughout MEKi treatment. The B lymphocyte kinase, Blk, exhibited increased binding at the 
late time point but no change in gene expression. Together, the comparison of RNAseq and 
kinome data are largely in agreement.  The notable distinctions, such as Kit and Blk, further 
substantiate the notion of a phenotypic shift throughout drug response.  
As an additional approach to global analysis, we employed pathway analysis of gene 
expression signatures 73. Using a panel of previously published gene signatures derived from 
human transcriptional profiles, pathway signature scores were derived from the mouse tumors 
using the shared Homologene ID (Fig. 2.11F). Clustering of the pathway signatures readily 
illuminated five distinct patterns of pathway activity (Fig. 2.11F, Fig. 2.12 5A-D). High pathway 
signature scores for Cluster 1 (related to mammary stem cells, basal-type breast cancer, and 
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fibroblasts) were observed in the untreated control tumors but not in MEKi-treated tumors. Thus, 
the tumors appeared to shift from mesenchymal-like to epithelial-like expression patterns after 1 
week of Trametinib treatment. Additionally, signature scores for pathways associated with 
immune response (e.g. T-cell, B-cell, CD8) increased in response to Trametinib. Indicative of 
pro-survival signaling, PI3K and AKT pathway scores were also increased over time. Despite 
some heterogeneity observed in each group, the signature scores for EMT_up and EMT_down 
were decreased and increased, respectively, over time on MEKi. Thus, the global pathway 
analysis corroborated the persistent survival of tdTomato-positive tumor cells we observed and 
provided stronger evidence for a shift to an epithelial state and immune response during 
treatment. 
As the pathway analysis had suggested a transcriptional response to an epithelial 
phenotype, we explored the relative expression levels of a subset of EMT-associated genes 
(Fig. 2.11G). Strikingly, genes associated with epithelial phenotype, such as E-Cadherin, were 
significantly increased in response to MEKi while those associated with mesenchymal 
phenotype were reduced. Changes in these EMT-associated genes were sustained during 
MEKi therapy in the early and late treatment groups. Gene list enrichment analysis by Enrichr 
reinforced this finding, as genes significantly upregulated at early and late time points were most 
enriched in the “Epithelium” gene set for Mouse Gene Atlas (Fig. 2.12E-H). 
Given the dramatic changes in the transcriptome observed in our model in response to 
MEKi, we surmised that lineage-specific transcription factors might drive the observed 
phenotypic shift. Therefore, we investigated the mouse transcription factors as a discrete gene 
subset (Fig. 2.12H, 2.12I). The Sox family of transcription factors are critical players in neural 
crest development and have been implicated in melanomagenesis 74,75. In response to MEKi, 
we observed a significant upregulation of Sox21 and downregulation of Sox5 and Sox10. 
Furthermore, two of the most significantly altered transcription factors at both time points were 
Zeb1 and Grhl2 (Grainy-head-like 2). Interestingly, Zeb1 and Grhl2 have been demonstrated to 
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participate in an intricate reciprocal regulatory feedback loop that governs EMT in breast cancer 
76,77. As validation of the transcriptome analysis, we performed immunoblotting and confirmed 
that E-cadherin (Cdh1) and pan-Cytokeratin increased in response to MEKi (Fig. 2.11J). 
Analysis of the transcriptome revealed that the adaptive kinome reprogramming and 
collagen reorganization occur in concert to promote persistence of melanoma cells for long-term 
survival on MEKi. Additionally, while EMT has been characterized as a potential mechanism for 
resistance to BRAFi, our gene expression analysis suggests the opposite, with increased 
epithelial signatures in drug treated tumors compared to control. These data represent a 
comprehensive view of drug response and highlight a potential importance of tumor cell 
interactions with the extracellular matrix for resistance to targeted therapy.  
2.4 Discussion  
We developed a highly localized 4-HT application method in an inducible GEM model 
that achieved reproducible spatiotemporal control of melanoma development on the mouse ear. 
We reproducibly tracked melanoma development from initial stages through advanced 
tumorigenesis, and then achieved long-term longitudinal studies of tumor response to therapy 
which closely mimics clinical response in patient settings (as summarized in Fig. 2.13).   
Our intravital imaging approaches allowed us to observe tumorigenesis from the single 
cell stage in vivo. We identified several reproducible phases of melanoma development in 
different animals. Early on, we visualized the development of clonal populations of melanoma 
cells directly in the dermis, which became densely packed pre-tumorous lesions that spread 
radially throughout the dermis, as it occurs in humans. By 2 months post 4-HT-application, 
melanoma grew vertically within the dermis to form palpable and spatially defined tumors.  
Through long-term longitudinal studies on MEKi in our melanoma model, we discovered 
that intratumoral reorganization, of both melanoma cells and bundled collagen, played a 
significant role in tumor cell survival on drug. The SHG signal tightly correlated with tdTomato+ 
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cells at early treatment stages, suggesting a dependency on bundled collagen for tumor cell 
survival. In the late stage on MEKi, however, this dependency abrogated at the cellular level, as 
heterogeneous regions of melanoma cells were present independent of collagen (depicted in 
Fig. 2.13, “Cellular level”). Structural intratumoral differences at different stages on drug, like the 
presence of tumor nests in regions of invasion across the cartilage boundary at the late stage 
on MEKi, could support protective mechanisms that enable long-term survival on drug. 
Additionally, while direct interaction with bundled collagen matrix was reduced in the late stage 
on MEKi, there is more collagen within tumors at this stage overall, compared to pre-treatment. 
These results suggest that the stiffening of tumors due to enhanced collagen deposition and 
tumor cell reorganization over time may be key switch that triggers tumor cell survival and 
resistance to targeted therapy. 
Furthermore, since tumor development in our model is controlled and temporally 
reproducible, we provide a more in depth and complete view of molecular plasticity on therapy 
in vivo. Analysis of our MIB/MS data revealed enhanced activity of the collagen binding receptor 
DDR1 at the early stage on MEKi, further promoting the idea that collagen promotes tumor cell 
survival against therapy. Although phenotype switching via “EMT” has previously been 
described as a means to promote drug resistance, we find evidence of a “MET” progression 
appears to enhance initial survival of melanoma cells against therapy. Comparing mRNA-seq 
and MIB/MS data of melanoma tumors in late versus early stages on drug, we have identified c-
Kit, EPHA1, CDK5, BLK, PTK6, and FGFR3, as potential drivers of functional resistance to 
MEKi in this model. 
By using a combination of novel approaches in our model system, we set the stage for 
new discoveries and understanding about tumor biology and therapeutic response. Coupling our 
imaging studies with transcriptome and kinome reprogramming analysis enables direct 
interrogation of tumor plasticity in vivo during drug response and the identification of properties 
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and potential therapeutic targets that promote resistance. Using these novel approaches, we 
have developed a model that enables direct observation of endogenous tumor development, 
tumor heterogeneity, and plastic response to targeted therapy at the endogenous cell level in 
situ. These methods will advance our basic understanding of the cellular processes involved in 
disease progression, increase the utility of existing and future GEM models, and aid in the 
testing of new therapeutics for malignant melanoma.  
2.5 Materials and methods  
Local 4-HT Application Method 
 
To achieve spatially controlled melanocyte recombination by local topical application, we 
applied 1μl of a 20mM concentration of 4-HT solution in DMSO, 100% Ethanol and Orange-6 
dye (the active ingredient in Henna skin tattoo dye to allow precise visualization of the region 
exposed to 4-HT in which CreER is activated), to the middle of the ear while the mouse was 
anesthetized. After 8-10 minutes, the area was vigorously washed with 70% EtOH to prevent 
transfer of tamoxifen to other areas and to ensure a single, controlled primary lesion (Fig. 2.1B). 
Using this method, we consistently induced local melanoma growth exclusively in the applied 
region in a reproducible fashion.  
Intravital Two-photon Microscopy 
Tumor-bearing animals with tumors between 10-30mm3 were imaged as previously 
described 32. Animals were anesthetized with 1-2% isoflurane on a heating pad equipped with 
temperature feedback, and tumors were imaged before and during the course of drug treatment 
studies. All imaging was performed at 1050 nm with an Olympus FV1000MPE mounted on an 
upright BX-61WI microscope, using a 25x, 1.05 N.A. (2 mm W.D.) water immersion objective 
with optical imaging gel with the same refractive index as water to capture images. A custom 
aluminum ear clamp, with 1) a bottom platform on which the ear rests and 2) an upper piece 
equipped with a pair of thumbscrews to secure the ear underneath a coverslip, facilitated 
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transfer of heat to the ear from an underlying heating plate/pad during imaging. Laser power 
(4%), software, and microscope settings (RXD2 and RXD4 channel PMT voltages at 850 and 
500, respectively) were consistent for all acquired images. The IR laser unit (MaiTai DeepSee, 
Sptectra-Physics) is tunable from 690–1300 nm with a pulse width < 100 fs. Two channel non-
descan detectors were used for image collection, and data was gathered with the Olympus 
Fluoview software.  
Macroscopic Imaging of tdTomato positive tumors 
Macroscopic imaging was performed on an Olympus MVX10 stereoscope system, and 
images were collected using Metamorph software and a color camera at 0.8X or 1X 
magnification. Fluorescent images were acquired using a mercury lamp and filter wheel for red 
fluorescence. Mice were anesthetized with 1-2% isoflurane and placed on a heating pad during 
imaging. Ears were flattened and stabilized to 5mL tubes with double sided tape to enable full 
macroscopic view of each tumor.  
Histology of tumor progression and tumor response to Trametinib 
Ears and lymph nodes were excised and fixed in 4% PFA at 4C for 24 hours. Tissues 
were then cryoprotected with fresh 30% sucrose at 4C for 24 hours. Ears and lymph nodes 
were then frozen in VWR Clear Frozen Section Compound (VWR 95057) using an ethanol / dry 
ice bath and were stored at -80C before sectioning. Sectioning and H&E staining were 
performed by the Cell Biology & Physiology Histology Core at UNC Chapel Hill.  
Drug treatments and further mouse protocols  
0.3mpk Trametinib (GSK212) conjugated in chow was fed to mice, which were 
harvested at 1, and 12 weeks on drug treatment. Tumor measurements were performed with a 
digital caliper every week during the course of each experiment, and measurements for length, 
width, and height were recorded (in mm). Tumor size was indicated by tumor depth. Mice were 
carefully monitored in accordance with our protocol.  
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Fluorescence Intensity Analysis 
Maximum intensity projections were made from z-stacks with 4μm intervals, taken with 
FV1000MPE two-photon, (roughly 20-40 slices per image, depending on tumor depth).  Average 
intensity was measured using Metamorph software analysis, and the intensity for each image 
was normalized by subtracting the value for background average fluorescence. Measurements 
were averaged for each time point, post-4-OHT application, plotted in Excel, and graphed in 
Prism. Each image was acquired with 4% laser power to maintain consistency.  
Multiplexed inhibitor bead (MIB) chromatography and mass spectrometry (MS) 
Snap-frozen tumors were crushed by mortar and pestle in ice-cold MIB lysis buffer 
(50mM HEPES, 150mM NaCl, 0.5% Triton X-100, 1mM EDTA, 1mM EGTA, pH 7.5) 
supplemented with complete protease inhibitor cocktail (Roche) and 1% phosphatase inhibitor 
cocktails 2 and 3 (Sigma). Extracts were sonicated 3 x 10s, clarified by centrifugation, and 
syringe-filtered (0.22um) prior to Bradford assay quantitation of concentration. Equal amounts of 
total protein (0.3mg) were gravity-flowed over multiplexed inhibitor bead (MIB) columns in high 
salt MIB lysis (1M NaCl).  The MIB columns consisted of 175ul mixture of six Type I kinase 
inhibitors (CTx-0294885, VI-16832, PP58, Purvalanol B, UNC-21474, and UNC-8088A) custom-
synthesized with hydrocarbon linkers and covalently linked to ECH-Sepharose beads as 
previously described 71. Columns were washed with 5mL of high salt (1M NaCl), 5mL of low salt 
(150mM NaCl) MIB lysis buffer, and 0.5mL low-salt lysis buffer with 0.1%SDS. Bound protein 
was eluted twice with 0.5% SDS, 1% beta-mercaptoethanol, 100mM Tris-HCl, pH6.8 for 15 min 
at 100C. Eluate was treated with DTT (5mM) for 25 min at 60C and 20mM iodoacetamide for 30 
min in the dark.  Following spin concentration using Amicon Ultra-4 (10k cut-off) to ~100 uL, 
samples were precipitated by methanol/chloroform, dried in a speed-vac and resuspended in 
50mM HEPES (pH8.0).  Tryptic digests were performed overnight at 37C, extracted four times 
with 1mL ethyl acetate to remove detergent, dried in a speed-vac, and peptides further cleaned 
using C-18 spin columns according to manufacturer’s protocol (Pierce). 
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RNA isolation, RNA-seq library preparation, RNA-seq and analysis 
A center section of each snap-frozen tumor was excised with a clean razor blade and 
RNA isolated using the RNeasy Plus Mini Kit (Qiagen) according to manufacturer’s protocol with 
the optional DNase I treatment (Qiagen) for 15min. 400ng total RNA was used as input for RNA-
seq library construction with a Kapa Stranded mRNA kit according to the manufacturer’s 
protocol. TruSeq adapter sequences were used for indexing. Library amplification was as 
described with 12 PCR cycles.  Equimolar amounts of each library were run as a 12-plex on a 
NextSeq 500—75 cycle, high output V2 kit. Expected read counts for genes were used as input 
for DESeq2 to identify differentially expressed genes 72. Differentially expressed gene sets 
(padj<0.1) were used as input for Enrichr 78 to identify pathway enrichments. Heat maps of log2 
transformed RSEM normalized expression values were generated using GENE-E software 
(Broad Institute). Normalized RSEM mouse gene values were converted to unique human gene 
IDs by shared homologene ID.  
Western Blotting 
Snap-frozen tumors were extracted in MIB lysis buffer (150mM NaCl) as above and 
filtered lysates were boiled in 1X SDS sample buffer for 10min at 100C. Equal amounts of lysate 
were separated by SDS-PAGE, transferred to nitrocellulose membrane, blocked with 5% milk in 
TBS, and subjected to immunoblotting with the following primary antibodies: phospho-ERK1/2 
(218/222), MEK1/2, phospho-MEK1/2, LCK, from Cell Signaling; ERK2 from Santa Cruz; RFP 
(to detect tdTomato) from. Secondary antibodies used were goat anti-Rabbit-HRP or goat anti-
mouse-HRP from Pierce.  SuperSignal West Pico Chemiluminescent Substrate (Thermo 
Scientific) was used and images were collected on a Biorad ChemiDoc.  
Liquid Chromatography, Mass Spectrometry and Analysis 
Peptides were resuspended in 2% ACN and 0.1% formic acid. 40% of the final peptide 
suspension was injected onto a Thermo Easy-Spray 75μm x 25cm C-18 column and separated 
on a 180min gradient (5-40% ACN) using an Easy nLC-1000. The Thermo Q Exactive mass 
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spectrometry ESI parameters were as follows: 3e6 AGC MS1, 80ms MS1 max inject time, 1e5 
AGC MS2, 100ms MS2 max inject time, 20 loop count, 1.8 m/z isolation window, 45s dynamic 
exclusion. Raw files were processed for label-free quantification by MaxQuant LFQ using the 
Uniprot/Swiss-Prot mouse database. Normalized LFQ intensities were plotted using GraphPad 
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Figure 2.1. Genetic incorporation of tdTomato enables visualization of melanoma 
initiation and growth with specific 4-HT application method. A) Diagram of PBT 
(Tyr::CreER;BRAFCA;PTENlox/lox;tdTomatoLSL) melanoma GEM model pre- and post- CreER-
induced recombination. B) Macroscopic images pre-, during, and post- 4-HT application on a 
single mouse ear. Olympus MVX10. Bar = 500μm. C) Macroscopic images with transmitted light 
and D) tdTomato fluorescence of tumor growth longitudinally over time on a single mouse ear, 
2-9 weeks post-4-HT application. E) Tumor growth, measured by tumor depth, over time. N³12. 






Figure 2.2. Achievement of reproducible spatial and temporal control of melanoma 
growth with <400 initiating cells. A) Intravital imaging set-up with Olympus MVX10 and B) 
Olympus FV1000MPE multiphoton. iPhone6 camera. C) 1µl 4-HT droplet, approximately 
2.7mm2. D) 9 max. intensity projections acquired within one 1.2mm2 region of the mouse ear. E) 
SHG, tdTomato, and Merge max. intensity projections of the dermis 40hours post-4-HT. Arrows 
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mark single melanocytes. Olympus FV1000MPE; 1050nm; 4% laser power. Bar = 50μm. F) 
Panel of macroscopic images with transmitted light of 20 different tumors, all 9 weeks post-4-









   
Figure 2.3. Visualizing melanoma development over time with cellular resolution. A) 
Intravital multiphoton images of tdTomato+ PBT melanoma development in the mouse ear over 
time; 0-9 weeks post-application of 20mM 4-HT. Second Harmonic Generation (SHG) reveals 
bundled collagen within the dermis of the ear. Images show merged SHG and tdTomato 
channels. FV1000MPE; 1050nm; 4% laser power. B) Normalized average intensity of tdTomato 
signal and C) SHG signal during tumor growth over time. N³12. D) H&E staining and E) 
 40 
Masson’s Trichrome staining of mouse ears 2, 6, and 8 weeks post-4-HT application. Olympus 
BX51; 10X Objective; Brightfield. F) Histology of tdTomato+ tumor growth at 2, 6, 7, and 8 
weeks post-application of 20mM 4-HT. Images display merged DAPI and tdTomato channels. 








Figure 2.4. BRAFV600E and PTEN-loss are required for tumor growth, which is temporally 
controlled and reproducible at the cell level. A) Intravital two-photon images of Tyr::Cre; 
tdTomatoLSL mouse ear, 2 weeks post-application of 20mM 4-HT. SHG and tdTomato acquired 
at 1050nm. Maximum intensity projections; FV1000MPE; 25X; 4% power. Scale bar = 50μm. B) 
Two-photon max intensity projections of PBT tumor development over time at 1, 3, 5, 7 and 9 
weeks post-application of 20mM 4-HT. Bar = 50μm. C) Merge of SHG and tdTomato at tumor 
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boundary in mouse ear, 4 weeks post-4-HT application. FV1000MPE; 1050nm; 25X; 4% power. 
Bar = 50μm. D) Histology of PBT mouse ears 4 days and 2, 6, 7, and 8 weeks post-application 






Figure 2.5. Heterogeneous response to MEKi over time. A) Macroscopic images of a PBT 
tumor without drug treatment 8, 9, 10, 14, and 16 weeks post-application of 20mM 4-HT and B) 
Macroscopic images of a PBT tumor over time pre- and 1, 5, 10 and 12 weeks on Trametinib 
therapy. C) Graphical representation of PBT tumor thickness / growth over time without MEKi 
Trametinib treatment and D) over time on MEKi therapy. N= N³4. Error bars = 95% CI. E) 
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Histology of tdTomato+ PBT tumor response to Trametinib at 1 week (early) and 7 weeks (late) 
on drug. Brightfield, DAPI, and tdTomato fluorescence acquired with Olympus BX51; 10X.   
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Figure 2.6. Amelanotic intratumoral nests are evident in persistent melanoma cell 
populations on MEKi. A) End-on view of melanoma ear tumor 8 weeks post-4-HT application 
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with tdTomato, DAPI, and bright field. 7μm thick section. Olympus BX51, 10X objective. B) 
tdTomato, DAPI, and bright field images of tumors pre-, 1 week, and 7 weeks on MEKi therapy. 





              
Figure 2.7. Intravital imaging reveals a relationship between bundled collagen and tumor 
cells for survival on MEKi. A) Intravital multiphoton imaging of tdTomato+ PBT melanoma 
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response to MEKi pre- treatment and at early (3 days), intermediate (3.5 weeks), and late (9 
weeks) stages on drug. Maximum intensity projections; FV1000MPE; 25X; 1050nm; 4% power. 
Scale bar = 50μm. B) Average Pearson’s correlation coefficients for SHG and tdTomato signals 
over time on MEKi treatment. N³9. Error bars = 95% CI. C) Masson’s Trichrome (MT) staining 
of histological slices of PBT melanoma at early and late time points (1 and 7 weeks) on MEKi. 
Blue signal represents intratumoral ECM and bundled collagen.  
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Figure 2.8. MEKi Experiment Overview. Graphical representation of the experimental design 
for longitudinal treatment and molecular analysis of melanoma response at early and late stages 
on continued treatment with MEKi (0.3mpk), compared to no drug control. Orange dots in (1) 
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represent 4-HT application, circular shapes represent no drug control (gray) and MEKi treated 
(blue) tumors. 6 tumors for each condition (no drug control, early, and late on MEKi) were 
harvested for molecular profiling. MIB/MS and mRNA-seq images are representative of results 




Figure 2.9. Adaptive kinome response to chronic and potent MEK inhibition. (A) 
Schematic representation of experimental MIB/MS workflow. (B) MIB binding (LFQ intensities) 
for MEK1 and MEK2 from untreated, early, and late tumors. ***, p<0.001. (C) Hierarchical 
clustering displayed as a heat map of mean-centered, log2-transformed LFQ intensities (MIB 
Binding) form untreated, early, and late tumors as in (A). Select panels are indicated and 
labeled with kinases by row. (D) Volcano plot showing log2 fold-change MIB binding (LFQ 
intensity) for early versus untreated tumors plotted against the –log10 p-value (FDR=0.05). 
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Dotted line, p=0.05. (E) Volcano plot showing log2 fold-change MIB binding (LFQ intensity) for 
late versus untreated tumors plotted against the –log10 p-value (FDR=0.05). Dotted line, 
















Figure 2.10. MEKi inhibits MAPK pathway throughout drug treatment. (A, B, and C) MIB 
binding (LFQ intensities) for (A) BRAF, (B) ERK1 and (C) ERK2 from untreated, early, and late 
tumors described in Fig. 5A. ***, p<0.001 (D) Principal component analysis of log2 (LFQ 
intensity) for kinases identified by MIB/MS in untreated and early and late Trametinib-treated 
tumors. (E) Immunoblotting to detect tdTomato expression from tumor lysates from untreated, 






Figure 2.11. Transcriptome profiling reveals dramatic phenotypic shift in response to 
Trametinib. (A) RNAseq analysis of untreated, early, and late tumors as log2-transformed 
RSEM normalized gene counts. Hierarchical clustering displayed as a heat map of the mean-
centered mouse kinase genes. (B) Volcano plot showing log2 fold-change (RNAseq) for early 
versus untreated tumors plotted against the –log10 p-value (FDR=0.05) as determined by 
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DESeq2. Dotted line, p=0.05.  (C) Volcano plot showing log2 fold-change (RNAseq) for late 
versus untreated tumors plotted against the –log10 p-value (FDR=0.05) as determined by 
DESeq2. Dotted line, p=0.05. (D) Log2 LFQ intensities (MIB binding) and Log2 RNAseq 
expression changes (early versus untreated) are plotted for kinases quantified by MIB/MS. (E) 
Log2 LFQ intensities (MIB binding) and Log2 RNAseq expression changes (Late versus 
Untreated) are plotted for kinases quantified by MIB/MS. (F) RNAseq data from untreated, early, 
and late tumors were used for Pathway Signature analysis and clustered. Representative 
signatures from each cluster are indicated at right. (G) Log2 fold change as determined by 
DESeq2 for select genes involved in EMT. (H) Volcano plot as in (B) for transcription factor 
genes. (I) Volcano plot as in (C) for transcription factor genes. (J) Western blots for indicated 




       
Figure 2.12. Classification of gene expression profile (A and B) and pathway activity 
signatures (C and D) using the principal component analysis (PCA) (A and C) and Silhouette 
Analysis (B and D) between untreated (black), 1 week MEKi (early, red) samples, and 12 weeks 
MEKi (late, green). (E-H) Up-regulated differentially expressed genes (cut-offs of log2FC ≥1 and 
padj≤0.05) determined by DESeq2 were used to query Enrichr for gene list enrichment analysis.  
The bar plots for GO Biological Process 2015 (E and G) and Mouse Gene Atlas (F and H) are 
shown for early (E and F) and late (G and H) time points on MEKi. 
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Figure 2.13. Graphical representation and model of results. Representation of tumor growth 
and response to MEKi at the macroscopic level, cellular and molecular levels. Representation of 
tdTomato+ melanoma and bundled collagen during tumor different phases of development and 
at early, intermediate, and late stages on MEKi. And illustrated diagram of key molecular hits 
that undergo plastic response over the course drug treatment. Graphic is based on intravital 
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imaging, MIB/MS, and mRNAseq of endogenous melanoma at different stages on treatment 





CHAPTER 3: CONCLUDING THOUGHTS AND FUTURE DIRECTIONS 
 
3.1 Overview 
Through development of our model system and incorporation of intravital imaging 
strategies, I have made multiple observations that require further thought and investigation. 
Some of these are described below in further detail.  
3.2 The extracellular matrix as a potential diagnostic of therapeutic resistance 
Brief introduction and importance of the ECM in pathology 
 
The extracellular matrix (ECM) is composed of approximately 300 proteins, known as 
the “matrisome” that assemble and rearrange in different patterns to generate the structural 
template for organs and tissues 79. Structural deregulation within a tissue, which is mediated by 
changes of the ECM composition, can promote pathology, particularly in cancer and fibrotic 
disease 80. In breast cancer, for example, tumor cells have been shown to migrate along 
collagen fiber tracks to promote invasion and metastasis 81,82. And enhanced intratumoral tissue 
stiffness due to excess production of LOX (lysyl oxidase), which crosslinks collagen fibrils, is a 
common indicator of increased malignancy 83,84. Additionally, deregulation of the ECM is thought 
to play a role in chronic wound settings, which are common in patients with diabetes, and 
treatment with fibronectin in chronic wounds has been shown to reduce disease state 85. 
The bulk of the ECM is primarily composed of three different types of proteins: 
collagens, proteoglycans, and glycoproteins (Fig. 3.1). Collagens make up the structural 
component of the ECM important for tensile strength, and are present in both fibrillar (collagens 
I-III, V, and IX) and non-fibrillar forms. 43 known collagens are present in mammals, and they 
are one of the most highly expressed proteins in the body 86. Proper regulation of collagen 
deposition and organization is critical during development, and loss of collagen elasticity due to 
 60 
degradation over time is a promoting factor of aging 87. Secondly, glycoproteins, such as 
fibronectin and laminins, bind to integrins and are critical for cell-ECM interactions. There are 
over 200 known glycoproteins, which can sequester soluble growth factors to further promote 
and inform migration and pro-survival cell signaling pathways. Interestingly, a recent and yet 
unpublished study from our lab by Dr. Seth Zimmerman shows that cells can generate and 
secrete their own fibronectin to promote directional migration. Furthermore, proteoglycans within 
the ECM can also bind soluble growth factor cues through interactions via their 
glycosaminoglycan (GAG) side chains. In both wound and tumor settings, the ECM is highly 
dynamic, and de-regulation of collagen crosslinking within the ECM has been shown to play a 
causative role in cancer pathogenesis 56.  
Intravital imaging is now becoming a more popular tool to investigate tumor behavior in 
response to therapy, and as I demonstrated in chapter two, second harmonic generation can be 
an extraordinary tool used to directly visualize bundled collagen reorganization and behavior in 
situ. We have shown that on treatment with the selective MEK1/2 allosteric inhibitor, Trametinib, 
bundled collagen can be rearranged and enhanced over time during tumor persistence. These 
results suggest a significant role for collagen and the ECM in resistance to therapy. Recently, 
another study with the BRAF inhibitor, PLX-4720, also showed that drug treatment influenced 
the tumor microenvironment, and surviving tumor cells existed in regions with high stromal cell 
populations prior to acquiring genetic resistance 58. These observations, made possible through 
intravital imaging techniques, illuminate the roles of the cellular and extracellular milieu within 
the tumor stroma in influencing innate and adaptive response to therapy. Since abnormal 
regulation of stomal ECM dynamics play a role in tumor progression, further longitudinal studies 
will be important in elucidating the interactions between tumor cells and the ECM during drug 
response to better characterize and inform therapeutic strategies. 
Future directions: using ECM as a marker of drug resistance 
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Traditionally, it is taught that there exists only a very minute population of cancer cells 
with stem-like properties that may persist on drug to promote tumor recurrence. However, based 
on our intravital imaging studies, this model is incorrect (at least with targeted therapy). Instead, 
while there is a significant initial de-bulking of the tumor cell mass on MEKi, with tumor depth 
decreasing approximately 30% within the first week on drug, a substantial population of 
melanoma cells survive. Direct visualization of intratumoral response to MEKi in our studies 
suggest that there exists a strong structural component to therapeutic resistance, which may 
initially be independent of genetic expression, but may influence cellular phenotype over time. 
These ideas are graphically represented in Figure 3.2.  
Understanding how targeted therapeutics affect the tumor microenvironment is critical 
for effectively treating melanoma. Tumor heterogeneity plays a substantial role in tumor 
resistance to targeted therapy. However, by performing intravital imaging of endogenous 
melanoma and bundled collagen in long-term longitudinal drug studies with MEKi, I discovered 
one common factor in persisting tumor cell populations. Based on our studies, surviving 
melanoma cells on MEKi co-localize with bundled collagen during initial stages on therapy. This 
suggests that tumor cell-ECM interactions along with increased deposition and concentration of 
collagen within a tumor may be a direct indicator of functional resistance to drug. With this in 
mind, early detection of enhanced bundled collagen presence may mark the “switching” point for 
when a tumor begins to regrow during the course of treatment. Below, I will outline several aims 
and future directions to further interrogate this idea.  
Depending on the tumor type, degradation of collagen or enhanced stiffness of a tissue 
can be frequently used to assess tumor development, progression and malignant status. Our 
studies demonstrated that the tumor ECM may be critical in initial melanoma cell survival on 
MEKi, and although our experiments were performed in an endogenous setting within a relevant 
genetic model of melanoma; still, these studies were performed in mice. To further interrogate 
this potential mechanism of tumor cell persistence, and to make a difference in clinical settings, 
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we need to validate this observation in human melanoma samples. First, I aim to perform 
second harmonic generation microscopy of patient biopsy samples using the same (or a similar) 
intravital imaging modality. The goal in mind here is to assess the disease state during the 
course of a patient’s treatment on a specific drug. Ideally, initial studies will incorporate tissue 
samples from patients on MEKi (Trametinib).   
There exists a significant need for new and improved biomarkers of tumor resistance, as 
the time in which a tumor becomes resistant to a therapeutic is still a relative guessing game. If 
we can identify similar changes in second harmonic generation in patient samples compared to 
our murine studies, we can develop a system to provide a clear biomarker or diagnostic for 
when a melanoma is adapting to drug in early stages. This “read-out” can be used to inform 
medical professionals to provide better treatment strategies for potentially prolonging a patient’s 
life.  
For these studies, we will need to design a special platform or stage-insert for patient 
tissue samples (a “biopsy grip”), and we will need to develop better software analysis tools to 
generate a specific diagnostic measure of intratumoral bundled collagen concentration and 
organization with high resolution and certainty. Already with image analysis, we can identify the 
status of bundled collagen deposition and arrangement within melanoma samples through 
measuring the average intensity (which will measure density), and the alignment (measuring 
reorganization) of collagen within the tumor. With improved analysis, this screen could 
potentially provide a clear diagnostic, with more collagen organization and bundling suggesting 
a condition reminiscent of the early stage on drug, where persistent tumor cell populations exist 
but have not yet reprogrammed to promote tumor regrowth; and less organization suggesting a 
late response with functional resistance emerging. One caveat for these studies is that we will 
also need to obtain a non-tumor control from patients for comparison.  
Finally, since histology played a key role in our results described in chapter 2, and since 
pathologists use traditional histology techniques and analysis to assess tumor status anyway, 
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we will to couple two-photon analysis with histological read outs. Ideally, we will use the same 
patient tissue sample for histology as we will use for our multiphoton imaging studies, so as to 
limit additional invasive procedures. Masson’s trichrome staining in our murine melanoma model 
identified the ECM as a further potential diagnostic of tumor persistence, as collagen presence 
was significantly enhanced in late stages on MEKi compared to early stages and no drug 
control. Therefore, combining these two techniques to analyze the ECM within individual tissue 
samples will provide further resolution for the identification of drug response status.  
If we accomplish these aims, my long-term goal will be to develop novel treatment 
strategies that incorporate this two-photon imaging regimen. If our finding holds true in human 
samples, and bundled collagen does in fact play a major role in therapeutic resistance, we can 
develop therapeutic regimes which include the use of ECM degrading enzymes. In fact, 
treatment with hyaluronidase, which degrades the ECM via catalyzing cleavage of hyaluronan 
(also upregulated in cancers), has previously been shown to enhance the efficacy of 
chemotherapy in melanoma and is regaining popularity 88. To develop a new therapeutic 
strategy, these studies will again need to be performed in mice. The goal overall goal of this 
investigation will be to identify the point in which a tumor begins to “switch” into a resistant state 
on drug, treat with hyaluronidase (or similar enzyme), and determine whether we can prolong 
and improve the effects of existing therapeutics.  
3.3 Broad future applications and ongoing studies 
 While I chose investigate response to targeted therapy in our 
Tyr::CreER;BRAFCA;PTENlox/lox;tdTomatoLSL melanoma GEM model for my main thesis project, 
this model can be used to characterize a multitude of ‘black box’ topics in melanoma research. 
Initially, I developed the precise 4-HT application method, controlling tumor growth in space and 
time, in order to generate a system that can be used to study the metastatic cascade. I was 
particularly interested in providing a platform that enabled tracking of endogenous tumor cell 
invasion, with the ability to readily identify distant colonization in vivo. This was made possible 
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through both my method of 4-HT application and the incorporation of the tdTomato fluorescent 
allele. One question that I failed to answer was: “what ‘phase’ of melanoma development at the 
two-photon level correlates with metastasis?” Our model, combined with intravital imaging, 
provides one of the first systems that can be used to serially track endogenous tumor growth 
from the individual cell stage. While pathologists can provide insight into how malignant a tumor 
is at a specific traditional ‘stage’ of melanoma growth (based on depth and radius), longitudinal 
studies need to be performed at the cell level to fully characterize the process of malignant cell 
transformation and invasion in situ.  
 Another huge black box in melanoma research pertaining to treatment strategies is: Do 
existing therapies inhibit or promote invasion and metastasis in vivo? While tumor shrinkage is a 
good indicator of successful response, metastasis is what ultimately kills people. Several 
problematic factors exist that limit our understanding and research of this question. For one, 
tumors in most murine models develop at different rates, and distinct treatment options in the 
clinic are available for different stages of melanoma progression (Table 1.1). Therefore, the 
answer to this question could rely on a number of variables, as one drug may be effective in 
blocking metastasis in one ‘stage’, but could fail in another.  
Beyond interrogating the success of a therapy at different stages of tumor development 
to answer this question, we also need to ask, “what stage on drug?” Tumors are remarkably 
heterogeneous, and a therapeutic agent can affect specific regions within a tumor more reliably 
than others due to both extrinsic (e.g. avascular regions with strong stromal components) and 
intrinsic factors (e.g. tumor cell genetic predisposition). Additionally, melanoma becomes 
resistant to existing therapies, and most GEM models can only mimic early stages of drug 
response, due to high initial tumor burden. Our system provides a more holistic view of drug 
response, as it provides a platform for long-term longitudinal studies. However, this question 
remains: does targeted therapy also inhibit metastasis? Based on the results from our study 
with MEKi (Chapter 2), we can develop hypotheses for how MEKi influences tumor cell invasion 
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and metastasis at early and late stages on drug. For example, we identified an increase in E-
Cadherin expression in late stages on MEKi. Recently, E-cadherin has been shown to be 
important for collective cell migration, which may play a critical role in disseminating from a 
primary tumor 33. Furthermore, PI3K and AKT signatures were increased throughout drug 
treatment, which have been characterized in other drug studies modeling resistance. Notably, 
these pathways signal to Rac, which can promote and influence migration patterns and 
behaviors through signaling to the actin cytoskeleton. While these initial findings suggest that 
MEKi may actually promote malignancy in prolonged treatment settings, more conclusive 
studies need to be performed to directly interrogate and evaluate whether this is true for 








Figure 3.1 The extracellular matrix: three key components of the matrisome. Graphical 
representation of a melanoma cell interacting with collagens, proteoglycans, and glycoproteins 















Figure 3.2 ECM dependency model for tumor cell persistence and functional resistance 
to drug. Traditional model of tumor response to therapy, where a pre-existing subset of tumor 
cells are genetically resistant to drug, compared to a new model, demonstrating structural 
dependency of bundled collagen for tumor cell persistence, followed by genetic expression 
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